检索结果-南通市图书馆

The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

引用

胰腺病学杂志(英文) 2024年第1期7卷 1-9页

作者： Cui Jiujie Fu Qihan Chen Xiaobing Wang Yanling Li Qi Wang Feng Li Zhihua Dai Guanghai Wang Yusheng Zhang Hongmei Liang Houjie Zhou Jun Yang Liu Wang Fenghua Zheng Leizhen Chen Xiaofeng Gong Ping Liu Jiang Yuan Ying Wang Lin Cheng Yuejuan Zhang Jun Zhou Yuhong Guo Weijian Zhan Xianbao Zou Zhengyun Li Da Zeng Shan Li Enxiao Li Zhiwei Teng Zan Cao Dan Kan Jie Xiong Jianping Quan Ming Yao Jiayu Yang Haiyan Wang Liwei Department of Medical Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China Department of Medical Oncology The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou China Department of Medical Oncology Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou China Department of Medical Oncology Shanghai General Hospital Shanghai Jiao Tong University Shanghai China Department of Medical Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China Department of Medical Oncology Sun Yat-sen Medical Hospital Sun Yat-sen University Guangzhou China Medical Oncology Chinese PLA General Hospital Beijing China Department of Gastrointestinal Oncology Shanxi Provincial Cancer Hospital Affiliated to Shanxi Medical University Taiyuan China Department of Clinical Oncology Xijing Hospital Air Force Medical University Xi’an China Department of Oncology and Southwest Cancer Center Southwest Hospital Third Military Medical University (Army Military Medical University) Chongqing China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing) Peking University Cancer Hospital &amp Institute Beijing China Cancer Center Department of Medical Oncology Zhejiang Provincial People’s Hospital People’s Hospital of Hangzhou Medical College Hangzhou China Department of Medical Oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China Oncology Department Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of Medicine Shanghai China Department of Oncology the First Affiliated Hospital with Nanjing Medical University Nanjing China Department of Oncology The First Affiliated Hospital School of Medicine Shihezi University Shihezi China Department of Oncology People’s Hospital of Xinjia

Objective: Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center ***: A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was ***: The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combined with oxaliplatin/cisplatin (GEMOX/GP) (7.6%). The AS and GS/X regimens were associated with the highest PFS ***: This is the first study to report multicenter, real-world data regarding advanced pancreatic cancer in China. Results revealed that real-world treatment options differed from guideline recommendations, and PFS was shorter than that in previously reported data. Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recomm

关键词： Advanced pancreatic cancer China Pancreas Data Center Chinese first-line regimens Real-world study

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：